Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carbamazepine
Drug ID BADD_D00356
Description Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965.[A180301] Aside from the above uses, this drug is also given to control the symptoms of bipolar 1.[L1335] Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder.[A180319]
Indications and Usage Carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia.[L1335] In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures.[A180301,L1335] Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive episodes caused by bipolar I disorder.[L1335] Some off-label, unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndrome.[A180415,A180421]
Marketing Status approved; investigational
ATC Code N03AF01
DrugBank ID DB00564
KEGG ID D00252
MeSH ID D002220
PubChem ID 2554
TTD Drug ID D04MSM
NDC Product Code 62512-0024; 30698-421; 50268-172; 60687-583; 63629-9292; 66993-409; 70518-3266; 70771-1470; 0615-8125; 0781-5987; 0904-6885; 49452-1705; 63552-060; 0078-0510; 0078-0511; 16571-681; 16714-064; 0093-0778; 17856-0029; 29033-019; 30698-419; 35561-355; 50090-0384; 51672-4047; 51672-4151; 54092-173; 60429-934; 60687-594; 63629-8721; 70518-0181; 70771-1469; 70954-240; 71205-025; 75834-220; 12658-0525; 12658-0526; 0904-7116; 42419-014; 35561-357; 51672-4149; 54092-171; 59746-789; 60505-2805; 63629-8743; 66993-407; 67386-621; 68788-7210; 70518-1433; 59746-790; 63629-8753; 68084-562; 68382-557; 70518-3176; 0781-5988; 16714-063; 27241-233; 29033-004; 29300-382; 35561-356; 51407-215; 60505-2807; 70518-1545; 71930-073; 72162-2021; 0781-8016; 0832-6022; 12658-0561; 12658-0565; 48087-0051; 70966-0020; 76003-0251; 13668-268; 0093-0109; 27241-232; 43063-328; 50268-170; 54092-172; 60505-2806; 68788-7825; 70518-1436; 70518-2242; 70518-3335; 71335-0461; 71335-0691; 71930-072; 75834-221; 0904-3854; 51927-2176; 13668-271; 51672-4125; 63629-8715; 68084-444; 68382-555; 70518-1769; 70518-2456; 70518-3699; 70518-3773; 0832-6023; 12658-0452; 51552-0653; 62991-1027; 65344-0028; 65344-0040; 0078-0512; 27241-231; 0121-0947; 43353-953; 59746-791; 70518-2426; 70518-3146; 71930-074; 72189-157; 0904-6172; 12658-0406; 12658-0541; 0078-0509; 0093-0090; 29033-020; 51672-4005; 51672-4123; 55154-1396; 60505-0183; 60687-479; 63629-8720; 68094-007; 68382-556; 70518-2841; 70518-3591; 70518-3694; 71335-1730; 12658-0486; 38779-0114; 48087-0052; 0078-0508; 16714-065; 30698-423; 50268-171; 51672-4150; 58118-0268; 66993-408; 68071-2701; 70518-2489; 70518-3174; 70771-1468; 0615-3505; 72664-218; 0832-6024; 65372-1102; 16571-680; 16571-682; 0121-1894; 50090-5740; 51672-4041; 51672-4124; 60429-032
UNII 33CM23913M
Synonyms Carbamazepine | Carbamazepine Acetate | Carbamazepine Dihydrate | Carbamazepine Hydrochloride | Carbamazepine L-Tartrate (4:1) | Carbamazepine Anhydrous | Carbamazepine Sulfate (2:1) | Carbazepin | Epitol | Finlepsin | Neurotol | Tegretol | Amizepine | Carbamazepine Phosphate
Chemical Information
Molecular Formula C15H12N2O
CAS Registry Number 298-46-4
SMILES C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Altered pitch perception19.21.01.011; 17.02.03.0180.000409%Not Available
Anisocoria17.02.11.009; 06.05.03.0130.000186%Not Available
Attention deficit hyperactivity disorder19.21.04.0040.000744%Not Available
B-cell aplasia01.02.02.0060.000186%Not Available
Behaviour disorder19.01.01.0050.000558%Not Available
Blood loss anaemia24.07.01.088; 01.03.02.0180.000372%Not Available
Cross sensitivity reaction10.01.01.0360.000372%Not Available
Cytotoxic lesions of corpus callosum17.02.10.030; 12.03.01.0620.000372%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.038--Not Available
Electric shock sensation17.02.07.024; 08.06.02.023--Not Available
Epileptic encephalopathy19.21.02.015; 17.12.03.0330.000186%Not Available
Eye symptom17.17.02.015; 06.08.03.0270.000186%Not Available
Fixed eruption23.03.05.008; 10.01.01.037; 08.01.06.0250.000279%Not Available
Focal dyscognitive seizures17.12.02.0050.000558%Not Available
Follicular mucinosis23.02.02.0110.000409%Not Available
Gait inability17.02.05.069; 08.01.02.0110.000651%Not Available
Gallbladder oedema09.03.02.0110.000186%Not Available
Haemophagocytic lymphohistiocytosis16.32.03.038; 10.02.01.077; 01.05.01.0260.000558%Not Available
Hepatic cytolysis09.01.07.0360.000279%Not Available
Hyperchromic anaemia01.03.02.0200.000186%Not Available
Hyperleukocytosis01.02.01.0180.000186%Not Available
Immune thrombocytopenia01.08.01.013; 10.02.01.0830.000558%Not Available
Lennox-Gastaut syndrome19.21.02.006; 17.12.03.0130.000186%Not Available
Mucosal disorder08.01.06.0290.000465%Not Available
Negative symptoms in schizophrenia19.03.04.0020.000186%Not Available
Periorbital swelling23.04.01.025; 10.01.05.025; 06.08.03.0320.000186%Not Available
Pharyngeal swelling22.04.05.0280.000186%Not Available
Potentiating drug interaction08.06.03.0150.000186%Not Available
Pregnancy on contraceptive18.08.01.0040.000186%Not Available
Pregnancy on oral contraceptive18.08.01.0050.000186%Not Available
The 31th Page    First    Pre   31 32    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene